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Summary
The 10b-acetyltransferase on the biosynthetic path-
way of the antineoplastic drug Taxol catalyzes the
regiospecific transfer of the acetyl group of acetyl-
coenzyme A (CoA) to 10-deacetylbaccatin III. We dem-
onstrate that in addition to acetyl group transfer, the
overexpressed enzyme also catalyzes the exchange
of propionyl and n-butyryl from the corresponding
CoA thioester to the hydroxyl group at C10 of the co-
substrate. Also, in vivo studies revealed that E. coli,
producingendogenousacetyl-CoAandoverexpressing
the recombinant acetyltransferase, can convert exoge-
nously supplied 10-deacetylbaccatin III to baccatin III.
Potentially, this heterologous in vivo productionmeth-
od in bacteria could be optimized to couple various
unnatural acyl-CoA analogs to myriad amino and/or
hydroxyl acceptors by acyltransferase catalysis; con-
ceivably, this process could facilitate the preparation
of second-generation Taxols.
Introduction
The biosynthetic pathway to the diterpenoid Taxol (pac-
litaxel), a potent mitotic drug used to treat several types
of cancer, includes five acyltransferase-catalyzed steps.
(Paclitaxel is the generic name for Taxol, which is a reg-
istered trademark of Bristol-Myers Squibb. Because of
the greater familiarity with the word ‘‘Taxol,’’ this will
be used throughout the manuscript.) Each operationally
soluble transacylase delivers an acyl group from a corre-
sponding acyl-coenzyme A (acyl-CoA) thioester to
a Taxol pathway intermediate [1–3]. Knowledge of the
structure-activity relationships of this drug reveals that
most of the acyl groups play a principal role in drug effi-
cacy. Notably, the N-benzoylphenylisoserine side chain
at C-13, the benzoyl at C-2, and the acetyl at C-4 are im-
portant pharmacophoric descriptors (Figure 1A) re-
quired for activity, whereas modification in the ‘‘northern
hemisphere’’ of the molecule at either the C-7, C-9, or C-
10 hydroxyl has negligible effect [4–6]. However, recent
investigations have demonstrated that when acyl group
substitution (propionyl or butyryl for acetyl) at the C-10
hydroxyl is coupled with simultaneous aroyl exchange
(2-furanoyl for benzoyl) at the C30 amide of Taxol
(Figure 1B), a synergistic effect with regard to enhanced
drug potency is observed for the modified Taxol com-
pared to the parent compound [7]. The current general
method used to synthesize analogs with various combi-
*Correspondence: walke284@msu.edunations of acyl group substitutions at, for example,
C-30N/C-10, starts with synthetic acylation of the C-10
hydroxyl of natural product 10-deacetylbaccatin III by
treatment with an acyl anhydride and cerium chloride
catalyst (Figure 2), followed by silyl group protection of
the C-7 hydroxyl, addition of the C-13 side chain via
a synthetically derived N-substituted b-lactam precur-
sor, and final deprotection [7] (Figure 2).
The favorable application of the described modified
Taxols possessing increased efficacy in both cytotoxic-
ity and microtubule assembly assays has prompted
a survey to assess whether the acyltransferases on the
Taxol biosynthetic pathway can regiospecifically trans-
fer novel acyl groups to the hydroxyls of advanced
metabolites on the Taxol pathway. The incorporation
of such biocatalysts into synthetic routes could poten-
tially eliminate the required protecting group manipula-
tion chemistry and circumvent the multistep aspect of
synthetic approaches toward the production of Taxol
analogs. Additionally, these enzyme catalysts can po-
tentially be used in mixed reactions pools to produce
an array of related molecules that have enhanced bioac-
tive properties.
Furthermore, it is postulated that the metabolic flux of
the Taxol biosynthetic pathway can be increased or de-
creased by altering the primary pathway or competitive
routes, respectively, through genetic modification of
Taxus-derived cell cultures [8, 9], and/or by engineering
a suitable host, e.g., Arabidopsis, to manufacture the
drug [10]. However, the complex matrix of taxoid metab-
olites in the Taxus plant, which includes Taxol, likely
contains pathway catalysts possessing broad substrate
specificity, particularly, since these enzymes have es-
sentially evolved in the presence of very closely related
compounds [11]. This consideration adds to the com-
plexity of genetically engineering the native organism,
or another suitable host, with a goal of directing pathway
flux to a single target molecule. It is conceivable, how-
ever, that each Taxol pathway enzyme could be altered
for desired catalytic properties through application of
random mutagenesis techniques, which often introduce
fortuitous mutations into a particular target gene [12–
16]. In general, these enzyme ‘‘breeding’’ methods
have produced catalysts with desired, targeted func-
tion, such as improved small-molecule enantioselectiv-
ity [12, 13] and modified substrate specificity [14–16].
Conceptually, such modification of Taxol pathway
genes could yield expressed enzymes with enhanced
catalytic efficiency for the natural substrates, and, hypo-
thetically, these genes could be engineered into cell cul-
tures of Taxus plants to increase pathway flux.
Although before the specificity of the Taxol pathway
acyltransferases can be altered through mutagenic
methods for application in transgenic biotechnology,
relevant physiological substrates that compete with
the desired natural substrate for enzyme active site oc-
cupancy must first be identified. For example, variously
substituted naturally occurring taxoids bear an acetyl
or benzoyl group at C10 [11], and, feasibly, the Taxus
10b-acetyltransferase could catalyze transfer of both
Chemistry & Biology
310groups. An assessment of the range of substrates uti-
lized by the acetyltransferase will determine substrate
binding and selectivity [17] and will provide a basis for
directing random or rational tailoring of the residues to
broaden or narrow specificity as desired.
Herein, we report on the regio- and substrate specific-
ity of the 10-deacetylbaccatin III 10b-O-acetyltransfer-
ase (DBAT), which was characterized initially by its ability
to catalyze the transfer of an acetyl group from acetyl-
Figure 1. Taxol and an Example of a Second-Generation Taxol An-
alog
(A and B) (A) Taxol in its native form; (B) a promising Taxol analog
derived from a combinatorial chemistry library possessing a propa-
noyl for acetyl substitution at C10 and a furanoyl for benzoyl re-
placement at the b-amine of the isoserinoyl side chain at C13.CoA to 10-deacetylbaccatin III to form baccatin III [18]
(Figure 2). A collection of acyl-CoA thioester substrates
was obtained from commercial sources or via synthetic
methods, and each thioester was incubated in vitro
with DBAT and 10-deacetylbaccatin III to profile the se-
lectivity and relative steady-state kinetics of the enzyme
for each CoA substrate. We also describe an in vivo
method utilizing E. coli, expressing the DBAT enzyme,
to produce baccatin III, a direct precursor of Taxol,
from exogenously fed 10-deacetylbaccatin III and en-
dogenous acetyl-CoA made by the bacteria.
Results and Discussion
The initial survey to identify Taxus acyltransferases
(among 16 members) that operate on the Taxol pathway
was based on the assembly of a sizable assay matrix
that included screening each transacylase against sev-
eral taxane variants and CoA thioesters that bore the
acyl groups of putative pathway intermediates. There-
fore, an assessment of extended substrate specificity
of DBAT was not conducted originally. However, now
that each of the five acyl/aroyltransferases involved in
Taxol biosynthesis has been isolated and characterized,
a more manageable assay matrix is evident, and, thus,
an evaluation of the substrate selectivity for novel acyl-
CoA thioesters of each functionally characterized acyl-
transferases has been initiated. The remaining 11 Taxus
acyltransferase clones of unknown function will ulti-
mately be incorporated into this investigation to charac-
terize their mode of action.
The selectivity of DBAT was examined with radiola-
beled natural substrate [13-3H]-10-deacetylbaccatin III
and several acyl-CoA compounds under standard assay
conditions [18], and bacteria expressing empty vector or
vector containing an acyltransferase that does not acyl-
ate at C10 were examined as control systems, as de-
scribed elsewhere [18]. Assays with the natural sub-
strate acetyl-CoA yielded a single peak eluting at 5.53
min (with coincident radioactivity and UV traces) fromFigure 2. Biosynthetic and Synthetic Routes to Taxol Analog Precursors
Outline of the biosynthetic reaction catalyzed by the 10-deacetylbaccatin III 10b-O-acetyltransferase (DBAT) in the presence of acetyl-CoA (R =
CH3), propionyl-CoA (R = CH3CH2), and butyryl-CoA (R = CH3CH2CH2) (route a). Outline of the semisynthesis of 10-acyl analogs of baccatin III
from 10-deacetylbaccatin III, acyl anhydrides, and cerium chloride (CeCl3) (route b). Abbreviations: TES-Cl, triethylsilyl chloride; pyr., pyridine.
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time of the biosynthetic product was identical to that
of authentic baccatin III. Identical radio-HPLC analysis
of enzyme-catalyzed products extracted from similar
assays incubated with the surrogate substrates pro-
pionyl-CoA and butyryl-CoA also revealed single peaks
eluting at 6.73 min and 8.63 min, respectively (Figure 3);
each identified peak possessed a coincident UV peak.
A taxane 2a-benzoyltransferase (TBT), from Taxus, was
expressed and isolated from JM109 cells as described
[19]. Assays with TBT, [13-3H]-10-deacetylbaccatin III,
and either acetyl-CoA, propionyl-CoA, or butyryl-CoA
showed no detectable product when analyzed by ra-
dio-HPLC as described.
Figure 3. Radio-HPLC Analysis of Products Catalyzed by the 10-b
Acetyltransferase
Radio-HPLC analysis of the biosynthetic products (retention time
Rt = 5.53, 6.73, and 8.53 6 0.01 min, respectively) generated from
[3H]-10-deacetylbaccatin III and acetyl-, propionyl-, and butyryl-
CoA by the recombinant 10-deacetylbaccatin III acetyltransferase.
Peak 1, [3H]-10-deacetylbaccatin III (DAB); peak 2, [3H]-baccatin III
(Bacc); peak 3, [3H]-10-propionyl-10-deacetylbaccatin III (PDAB);
peak 4, [3H]-10-butyryl-10-deacetylbaccatin III (BDAB). HPLC con-
ditions: 40:60 acetonitrile/water.A preparative-scale (6 L) culture of the JM109 bacteria
harboring the dbat gene was grown for expression of the
operationally soluble DBAT enzyme, which was subse-
quently isolated and partially purified as described
previously [18]. Portions of this concentrated enzyme
fraction were incubated with 10-deacetylbaccatin III
and acetyl-CoA, propionyl-CoA, or butyryl-CoA in an at-
tempt to generate enough biosynthetic product to eluci-
date the structure and determine the regiochemistry of
the isolated material as the 10-acetylated material, bac-
catin III, 10-propionyl-10-deacetylbaccatin III, or 10-bu-
tyryl-10-deacetylbaccatin III, respectively, by 1H-NMR
analysis. Only baccatin III and the putative 10-pro-
pionyl-10-deacetylbaccatin III analog were made in
sufficient quantity (R1 mg, w1.6 mmol) to confirm by
1H-NMR that the product was monoacylated by DBAT
at only the C10 hydroxyl, and not at the C1, C7, or C13
hydroxyl of the diterpene (cf. Figure 2 for numbering),
thus validating the regiospecificity of the enzyme. The
1H-NMR data for the biosynthetically derived baccatin III
were identical to the data reported for this compound
[18]. The diagnostic singlet observed at d 6.29 corre-
sponds to the signal for H10 that is attached to a carbon
bearing the C10 acetoxy functional group. Protons H7
and H13 of methine carbons (CH), each bearing a hy-
droxyl group, were observed comparatively as upfield
signals at d 4.43 and d 4.83, respectively (Table 1). Like-
wise, the 1H-NMR spectrum of the 10-propionyl-10-de-
acetylbaccatin III analog contains a diagnostic singlet
for the H10 signal at d 6.32 (Table 1) that is consistent
with the chemical shift of hydrogen attached to a me-
thine bonded to an acyloxy functional group. The H7
and H13 signals are upfield at d 4.44 and d 4.88, respec-
tively, as observed for baccatin III. The relative deshield-
ing effect of the acyloxy at C10 on the chemical shift of
H10 is apparent if the upfield H10 signal (at d 5.24) of
10-deacetylbaccatin III, possessing only a hydroxyl at
C10 (Table 1), is compared. The identity of the propionyl
group is further confirmed by upfield chemical shifts forTable 1. A Listing of the 1H-NMR Data of 10-Deacetylbaccatin III and Its Various Biosynthetically Derived 10-Acetylated Analogs
H 10-DAB Baccatin III 10-PDAB
2 5.62, d, 7 5.59, d, 7 5.60, d, 7
3 4.27, m 3.84, d, 7 3.87, d, 7
5 4.96, d, 8 4.98, bd, 8 4.97, d, 8
6a 2.58, m 2.52, m 2.54, m
6b 1.86, m 1.83, m 1.85, m
7 4.29, m 4.43, m 4.44, m
10 5.24, s 6.29, s 6.32, s
14 2.32, d, 6.0 2.26, d, 6.3 2.28, d, 5.4
13 4.86, bt 4.83, bt 4.88, m
16 + 17 1.08, s 1.07, s 1.09, s
18 2.12, s 2.02, s 2.04, s
19 1.81, s 1.64, s 1.65, s
20a 4.15, d, 8 4.27, d, 8 4.29, d, 8.5
20b 3.99, d, 7 4.12, d, 8 4.13, d, 8.5
Ar 8.03, d; 7.62, t; 7.51, t 8.07, d; 7.58, t; 7.45, t 8.1, d; 7.59, t; 7.46, t
4-OAc 2.36, s 2.25, s 2.27, s
10-OAcyl not applicable 2.21, s 2.52, m; 1.22, t, 4
300 MHz 1H-NMR data for authentic 10-deacetylbaccatin III (10-DAB), and for baccatin III and 10-propionyl-10-deacetylbaccatin III (10-PDAB)
derived biosynthetically from assays incubated with acetyl-CoA and propionyl-CoA, respectively, 10-DAB, and DBAT. The bold text highlights
the distinct chemical shift differences between the 10-deacyl- and 10-acylbaccatin III molecules at H10 and the side chain protons of the 10-acyl
group. Samples were dissolved in CDCl3 and were analyzed at 300 K: d in ppm, multiplicity, J (coupling) in Hz. Abbreviations: s, singlet; d, dou-
blet; t, triplet; bt, broad triplet; m, multiplet.
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312the CH3 and CH2 protons at d 1.22 and d 2.52, respec-
tively, of the alkanoyl side chain.
The comparatively poorer catalytic efficiency of DBAT
in assays with butyryl-CoA and 10-deacetylbaccatin III
resulted in low production (w0.16 mmol) of the butyryl
baccatin analog. Consequently, the acquisition of
1H-NMR data for this biosynthetic product was pre-
cluded, despite efforts to process assays on a prepara-
tive-scale slightly greater than that used in assays with
propionyl-CoA (described above). Therefore, the regio-
specificity of the butyryl group transfer to the taxane
core had to be confirmed by comparison of HPLC-UV
profiles of authentic standards to that of the product
catalyzed by DBAT in the presence of 10-deacetylbac-
catin III and butyryl-CoA. The retention time (Rt = 6.51
min) of authentic 10-butyryl-10-deacetylbaccatin III
was identical to that of the biosynthetic butyryl product,
while authentic 7- and 13-butyryl-10-deacetylbaccatin
III eluted at 8.56 min and 6.35 min, respectively (Figure 4),
thus indicating that DBAT transfers the butyryl group
from the corresponding CoA thioester to the C10 hy-
droxyl of the diterpene cosubstrate.
Further product analysis included combined LC-elec-
trospray ionization mass spectrometry or fast atom
bombardment ionization to confirm that products of the
correct molecular weight were obtained for monoacyl-
ated product (MH+ at m/z 587 for baccatin III, at m/z
601 for the proprionyl derivative, and at m/z 615 for the
butyryl derivative). The MH+ molecular ions of each bio-
synthetically derived product fragmented into diagnostic
ions at m/z 527 (M+ 2 alkanoic acid at C10) and m/z 509
(m/z 527 2 H2O).
The relative specificity constant (Vmax/Km) of each
processed CoA was calculated from the amount of
Figure 4. Comparison of a Biosynthetically Derived Butyryl-10-
Deacetylbaccatin III Regioisomer to Authentic Standards
The solid line trace shows the HPLC-UV profile (A228) of the com-
pounds isolated from the enzyme-catalyzed reaction of 10-deacet-
ylbaccatin III and butyryl-CoA incubated with recombinant DBAT
enzyme. The de novo product elutes at Rt = 6.51 6 0.01 min. The
large peak at 3.54 min is unconsumed 10-deacetylbaccatin III
(DAB) substrate. The superimposed dashed line trace shows the
HPLC-UV profile (A228) of a mixture of authentic 13-butyryl-10-
deacetylbaccatin III (Rt = 6.35 min, 13-BDAB), 10-butyryl-10-deace-
tylbaccatin III (Rt = 6.51 min, 10-BDAB), and 7-butyryl-10-deacetyl-
baccatin III (Rt = 8.56 min, 7-BDAB). The peak corresponding to the
biosynthetically derived product coincides with that for the authen-
tic 10-butyryl analog and thus verifies that DBAT transfers the bu-
tyryl group of the corresponding coenzyme thioester specifically to
the C10, and not to the C7 or C13, hydroxyl of 10-deacetylbaccatin
III. HPLC conditions: 60:40 acetonitrile/water.10-acylated product made from the corresponding thio-
ester in a competitive substrate reaction under typical
assay conditions, and the resulting product mixture
was analyzed by reverse-phase HPLC with UV monitor-
ing (A228) of the effluent. The relative absorbance max-
ima of each baccatin derivative were compared directly
(the extinction coefficient of each product was assumed
to be virtually identical for each alkanoyl baccatin analog
since no additional strongly UV-absorbing chromophore
was added to the substrate during catalysis). Relative to
the specificity constant of DBAT for the native acetyl-
coenzyme substrate (Vmax/Km = 3.0 s
21nM21), pro-
pionyl-CoA was at 1.6 s21nM21 and butyryl was lower
at 0.16 s21nM21. CoA thioesters of branched chain
alkanoyls (iso-butyryl and iso-valeryl, also known as
2-methylpropionyl and 3-methylbutyryl, respectively),
n-alkanoyls greater than C4 (n-pentanoyl and n-hexa-
noyl), cyclohexanecarboxyl, benzoyl, and, intriguingly,
the C4 trans-butenoyl were all unproductive substrates;
i.e., transesterification by DBAT with these substrates
was below detectable limits. These data suggest that
the length of the alkyl side chain plays an important
role in the steric interaction between substrate and en-
zyme. Additionally, in light of the productive transfer
by DBAT of the C4 n-butyryl group to the hydroxytaxane,
the presence of the p bond in the trans-butenoyl-CoA
suggests that the active site of DBAT is conformational
exclusive of the locked C4-transoid configuration and/or
that the p electrons are electronically restrictive.
Second-generation Taxol analogs have been synthe-
sized with propionyl or butyryl substitutions at C10 of
the taxoid core, and such compounds have demon-
strated improved cytotoxicity and tubulin binding prop-
erties relative to the parent drug [7]. Therefore, DBAT
biocatalysis holds promise as an alternative method
for the production of unnatural baccatin III compounds
that can serve as intermediates in biosynthetic or semi-
synthetic routes to manufacture modified Taxols.
Potential Application of DBAT in the Semisynthesis
of Taxol and Its Analogs
Naturally occurring Taxol is found in several subspecies
of the Yew (Taxus) at relatively low concentrations com-
pared to other taxanes, including the closely related ad-
vanced biogenetic precursor 10-deacetylbaccatin III,
which is extractable atw5- to 10-fold higher concentra-
tions from renewable portions of the Yew [11]. A current
practical semisynthesis of Taxol derives from coupling
a phenylisoserinyl precursor to baccatin III, which is syn-
thesized by selective acetylation of 10-deacetylbaccatin
III at C10 [20]. This latter acylation has posed a synthetic
challenge due to the order of increasing reactivity of the
hydroxyl groups (at C1 < C13 < C10 < C7, the most re-
active) of 10-deacetylbaccatin III (see Figure 1 for num-
bering) that can be acylated [21–23]. Consequently,
methods have been developed to regioselectively acet-
ylate the hydroxyl at C10, and not at the more reactive
C7. These procedures include the addition of a remov-
able silyl protecting group at C7 followed by acetylation
at C10, and direct acetylation of 10-deacetylbaccatin III
(without the use of protecting groups) is achieved by re-
action with methyliminium salts [24] and acetic anhy-
dride in the presence of a Lewis acid (CeCl3, LiCl,
ZnCl2, or YbCl3) (Figure 2) [25].
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is added before or after acetylation of the hydroxyl at
C10 of 10-deacetylbaccatin III, the C7 hydroxyl ulti-
mately still needs to be protected prior to coupling the
synthetically derived phenylisoserine side chain precur-
sor at C13 of baccatin III enroute to Taxol [26–29]. Alter-
natively, semisynthetic approaches that do not rely on
protecting group manipulation chemistry to construct
Taxol and its analogs will foreseeably involve enzyme
catalysts. In this context, DBAT has been shown to re-
giospecifically transfer acetyl (natural donor) as well as
propionyl and n-butyryl from the corresponding CoA
thioesters to the C10 hydroxyl of 10-deacetylbaccatin III
by using ‘‘green chemistry’’ methodology without heavy
metal Lewis acid catalysts, organic solvents, or silyl and
2,2,2-trichloroethyl chloroformate protecting groups at
other reactive hydroxyls.
Furthermore, in vivo biosynthetic production of me-
tabolites occurring early in the Taxol biosynthetic path-
way has been successful in bioengineered Arabidopsis
[10] and E. coli [30]. Engineering additional downstream
enzymatic steps on the pathway to Taxol and related
compounds into a bacterial system may be limited by
the need to target and express in active form at least
19 total genes that include a family of membrane-tar-
geted cytochrome P450 monooxygenases. Therefore,
Taxus plant genes will likely be more suitably expressed
in the native host or in another plant system such asAra-
bidopsis or suitable crop plant [10] that has the requisite
plant organelles for enzyme and metabolite targeting
and trafficking. However, we have demonstrated that
E. coli, expressing the dbat gene, can be used as a pliant
host to synthesize an obligatory intermediate on the
Taxol pathway via an abundant natural product precur-
sor. Bacterial culture (100 ml) expressing dbat converts
w20% (50 nmol) of exogenously fed 10-deacetylbacca-
tin III (at 250 mM) to baccatin III in 16 hr (without optimi-
zation of expression or growth conditions), and the
in vivo DBAT enzyme uses endogenous acetyl-CoA
from E. coli as a cosubstrate. Separate HPLC analyses
with UV monitoring (A228) of organic extracts derived
from the medium, and the pelleted cells of JM109 E. coli
used in the feeding study, showed that approximately
90% of the baccatin III produced (eluting at 7.69 6
0.01 min) (Figure 5) was found in the medium, while the
remaining 10% of de novo product was associated
with the cells. This observation suggests that the
E. coli cells export a bulk of baccatin III to the growth
broth, thus making the purification of baccatin III mark-
edly easier than acquiring this metabolite from its natu-
ral resource, Taxus leaves. For a negative control ex-
periment, JM109 E. coli cells possessing a plasmid
expressing TAX02 (a related Taxus-derived 2a-O-ben-
zoyltransferase) were processed identically to bacteria
expressing DBAT; these cells did not produce baccatin
III above the detection limits of the analysis.
Significance
Recombinantly expressed DBAT has modest sub-
strate flexibility for alkanoyl-CoA cosubstrates and
catalyzes the regiospecific transfer of the alkanoyl to
the C10 hydroxyl of 10-deacetylbaccatin III. This pre-liminary screen of DBAT provides a baseline for guid-
ing enzyme ‘‘breeding’’ procedures that will supply
mutants of the acyltransferase; the so-derived mutant
enzymes will be screened for novel acyltransferase
function. Ideally, mutant enzymes that possess en-
hanced turnover for the natural substrate or expanded
selectivity for unnatural substrates can be acquired by
these random mutagenesis methods. In addition to
being tractable for the discovery of novel catalytic
function, these investigations will, in general, provide
a priori insight into the structural/functional domains
and conserved motifs of the family of Taxus acyltrans-
ferases, which belong to a larger superfamily, desig-
nated BAHD [31]. Currently, the regio- and substrate
specificity of the other acyltransferases on the Taxol
pathway are being investigated through in vitro as-
says, and, as with DBAT, mutants of these enzymes
will be developed and screened for novel function.
Furthermore, the in vivo production of baccatin III is
attainable in E. coli transformed with DBAT, and thus
precludes the need to employ genetic engineering
techniques on Taxus plant cell cultures to express
the acetyltransferase for the production of elevated
levels of the metabolite. Optimization of the semibio-
synthetic method in bacteria potentially provides a
practical means of developing commercial-scale pro-
duction of baccatin III, which serves as a key interme-
diate to Taxol in semisynthesis and biosynthesis.
Moreover, application of this in vivo method with the
other acyltransferases in the Taxol biosynthetic path-
way imaginably could spawn alternative methods for
the semibiosynthetic production of a library of sec-
ond-generation pharmaceuticals with modified acyl
groups. A practical model of the application of the het-
erologous expression of plant genes in bacteria is the
large-scale, in vivo production, in E. coli, of pharma-
ceutically important analogs of the plant-derived ate-
misinin, a secondary natural product of Artemisia
used to treat malaria [32].
Figure 5. HPLC Analysis of the In Vivo Production of Baccatin III
from 10-Deacetylbaccatin III
HPLC analysis of the biosynthetic product (retention time Rt =
7.69 6 0.01 min, arrow) generated in vivo from 10-deacetylbaccatin
III fed to E. coli. The solid line trace shows the UV (A228) profile of
products isolated from E. coli cells expressing DBAT enzyme
(TAX06); the dashed line trace shows the UV profile of products
isolated from E. coli expressing TAX02, which regiospecifically
acylates the C2 hydroxyl of taxoids. HPLC conditions: 30:70 aceto-




A Varian Inova-300 or a Varian UnityPlus500 instrument was used to
acquire proton nuclear magnetic resonance spectra. A Finnigan LC-
ESI LCQ Deca XP tandem mass spectrometer (Thermo Electron
Corp.) or a JEOL AX-505 Fast Atom Bombardment ionization double
focusing mass spectrometer was used for mass spectral analysis.
An Agilent 1100 HPLC system equipped with a Packard Radiomatic
Flow-One Beta 150TR radioactivity detector (PerkinElmer, Shelton,
CT) was used for tandem liquid chromatography with UV detector
and radioactivity monitoring of effluent mixed with 3a70B Complete
Counting Cocktail (Research Products International, Mount Pros-
pect, IL).
Substrates and Reagents
[13-3H]-10-Deacetylbaccatin III (1.2 Ci/mol) was synthesized as de-
scribed elsewhere [33]. [3H]Sodium borohydride was purchased
from American Radiolabeled, Inc. (St. Louis, MO). 10-Deacetylbac-
catin III was purchased from Natland (Research Triangle Park,
NC). CoA, as the lithium salt, and acetyl, propionyl, n-butyryl and
iso-butyryl, 2,3-butenoyl (crotonyl), iso-valeryl-, n-hexanoyl-, and
benzoyl-CoA thioesters were purchased from Sigma. All other re-
agents were purchased from Sigma-Aldrich and were used without
further purification unless indicated otherwise. Valeryl- and cyclo-
hexanecarboxylic acid-CoA thioesters were synthesized by estab-
lished procedures [19, 34]. Briefly, to a solution of pentanoic acid
(Aldrich) or cyclohexanecarboxylic acid (Aldrich) (55 mmol) in
CH2Cl2/tetrahydrofuran (5:2, vol/vol, 10.5 ml) under N2 was added
triethylamine (60 mmol, 8.5 ml) in one portion, and the mixture was
stirred for 10 min at room temperature. Ethyl chloroformate
(55 mmol, 5.3 ml, 1 equivalent) was added in one portion, and the re-
action was stirred for 1 hr at room temperature. The solvents were
evaporated, and the residue was dissolved in 0.5 ml t-butyl alcohol.
CoA as the sodium salt (47.6 mg, 61 mmol dissolved in 1.0 ml of 0.4 M
NaHCO3) was added to the solution, and the mixture was stirred for
0.5 hr at room temperature, then quenched with 1 M HCl (4 ml,
1 equivalent relative to NaHCO3) and adjusted to pH 5 with 15 mM
NaH2PO4 (pH 4.8). The solvents were evaporated under reduced
pressure (5 hr) at room temperature. The residue was resuspended
in 15 mM NaH2PO4 (pH 6.9, 7 ml). The crude product was purified by
flash chromatography on a C18 silica gel (VWR) column that was first
washed with methanol and water, then equilibrated with 15 mM
NaH2PO4 (pH 6.9). The crude sample was loaded onto the column,
which was eluted with 5 ml portions of increasing methanol in
15 mM NaH2PO4 (pH 6.9) to yield valeryl- or cyclohexanoyl-CoA
(eluted in 10%–15% methanol). The purity (estimated at 96%) of
each CoA thioester was assessed by analytical thin layer chroma-
tography (TLC) (silica gel developed with 1-butanol/H2O/AcOH,
5:3:2, vol/vol/vol) and 1H-NMR analysis. The 1H-NMR spectra com-
pared favorably with those of other, closely related and commer-
cially available alkanoyl-CoA thioesters. The valeryl-CoA or cyclo-
hexanoyl-CoA esters were lyophilized, weighed, and resuspended
in water tow500 mM.
Synthesis of 7-Butyryl-10-Deacetylbaccatin III
To a solution of 10-deacetylbaccatin III (50 mg, 92 mmol) in 2 ml pyr-
idine was added butyryl chloride (95 ml, 0.92 mmol), and the reaction
mixture was stirred overnight at room temperature. The mixture was
partitioned between water (20 ml) and ethyl acetate (20 ml) and was
stirred for 30 min. The aqueous layer was isolated and further ex-
tracted with ethyl acetate (3 3 20 ml); the organic fractions were
combined and extracted with aqueous saturated copper sulfate
solution (4 3 20 ml) to remove pyridine. The ethyl acetate was dried
over magnesium sulfate, filtered, and evaporated in vacuo. The
7-butyryl-10-deacetylbaccatin III (Rf = 0.44) was purified from the re-
action mixture by preparative TLC (40:60 hexane/ethyl acetate). The
yield of the target product was 10 mg (18% yield [without optimiza-
tion of the synthesis], 98% pure by 1H-NMR). 1H-NMR (300 MHz,
CDCl3) d: 0.90 (t, J = 7.5 Hz, CH3CH2CH2C=O), 1.04 (s, H16), 1.06
(s, H17), 1.57 (tq, J = 7.5 Hz, J = 7.5 Hz, CH3CH2CH2C=O), 1.82 (s,
H19), 1.90 (m, H6b), 2.10 (bs, H18), 2.20 (t, J = 7.5 Hz, CH3
CH2CH2C=O), 2.23 (d, J = 5.1 Hz, H14), 2.28 (s, CH3C=O at C4),
2.52 (m, H6a), 4.06 (d, J = 6.9 Hz, H3), 4.13 (d, J = 8.1 Hz, H20b),4.32 (d, J = 8.1 Hz, H20a), 4.86 (bt, J = 8.1, H13), 4.94 (d, J = 9.6 Hz,
H5), 5.33 (s, H10), 5.51 (dd, J = 10.8 Hz, J = 7.2 Hz, H7), 5.61 (d, J =
6.9 Hz, H2), 7.48–8.10 (aromatic-H).
Synthesis of 10-Butyryl-10-Deacetylbaccatin III
The following procedure is adapted from established methods [35].
To a solution of 7-triethylsilyl-10-deacetylbaccatin III (32 mg, 50
mmol) [36] in 1.5 ml dry THF at 240ºC was added lithium bis(trime-
thylsilyl)amide (65 ml, 66 mmol). The solution was stirred for 5 min,
and butyryl chloride (7 ml, 66 mmol) was added dropwise. The reac-
tion was warmed to 0ºC, quenched by the addition of saturated
aqueous ammonium chloride solution (20 ml), and then extracted
with ethyl acetate (3 3 10 ml). The organic fractions were combined
and washed with brine and were dried over anhydrous magnesium
sulfate. The solvent was decanted then removed in vacuo, and the
remaining crude residue containing the acylated product was dis-
solved in 1 ml dry THF and cooled to 0ºC. A solution of 30% HF in
pyridine was added dropwise (over 1 hr) to the material to remove
the silyl protecting group. The reaction was quenched by the addi-
tion of sodium bicarbonate to neutralize the reaction and partitioned
against ethyl acetate. The organic layer was isolated and saved, and
the aqueous fraction was extracted with ethyl acetate (23 5 ml). The
organic fractions were combined and extracted in series with brine
and water; the organic solvent was dried over anhydrous magne-
sium sulfate, decanted, and removed in vacuo. The remaining crude
residue was loaded onto a preparative silica gel TLC plate and eluted
with 40:60 hexane/ethyl acetate. The band of silica gel correspond-
ing to the product (Rf = 0.37) was isolated and extracted with ethyl
acetate, and the organic layer was decanted and evaporated to yield
pure 10-butyryl-10-deacetylbaccatin III (10 mg,w30% yield [without
optimization of the synthesis], 98% purity by 1H-NMR). 1H-NMR
(300 MHz, CDCl3) d: 1.01 (t, J = 7.5 Hz, CH3CH2CH2C=O), 1.08 (s,
H16 and H17), 1.65 (s, H19), 1.73 (tq, J = 7.5 Hz, J = 7.5 Hz,
CH3CH2CH2C=O), 1.84 (m, H6b), 2.03 (s, H18), 2.26 (s, CH3C=O at
C4), 2.27 (d, J = 7.7 Hz, H14), 2.46 (m, CH3CH2CH2C=O), 2.54 (m,
H6a), 3.87 (d, J = 7 Hz, H3), 4.13 (d, J = 8.4 Hz, H20b), 4.29 (d, J =
8.4 Hz, H20a), 4.45 (dd, J = 10.8 Hz, J = 6.9 Hz, H7), 4.87 (bt, J = 8,
H13), 4.97 (dd, J = 9.6 Hz, J = 1.8 Hz, H5), 5.60 (d, J = 7 Hz, H2),
6.30 (s, H10), 7.46–8.08 (aromatic-H).
Synthesis of 13-Butyryl-10-Deacetylbaccatin III
Briefly, to a solution of 7-triethylsilyl-10-deacetylbaccatin III [37]
(100 mg, 152 mmol) in 3 ml dry THF, cooled to 240ºC, was added
1.0 M lithium bis(trimethylsilyl)amide (167 ml, 167 mmol). The solution
was stirred for 5 min, and triethylsilyl chloride (28 ml, 167 mmol) was
added dropwise. The reaction was warmed to 0ºC, quenched by the
addition of saturated aqueous ammonium chloride solution (20 ml),
and extracted with ethyl acetate (3 3 10 ml). The organic fractions
were combined and dried over anhydrous magnesium sulfate; the
solvent was decanted and removed in vacuo. The crude bis(silyl)-
protected product was purified by preparative TLC (50:50 hexane/
ethyl acetate), the sample at Rf = 0.8 was isolated from the silica
gel by extraction with ethyl acetate, and the solvent was evaporated.
To the remaining residue, 7,10-bis(triethylsilyl)-10-deacetylbaccatin III
(w30 mg, 39 mmol), dissolved in 3 ml dry THF at 240ºC was added
lithium bis(trimethylsilyl)amide (42 ml, 43 mmol). The solution was
stirred for 5 min, and butyryl chloride (4.6 ml, 43 mmol) was added
dropwise. The reaction was stirred for 30 min, warmed to 0ºC,
quenched by the addition of saturated aqueous ammonium chloride
solution (20 ml), and then extracted with ethyl acetate (3 3 10 ml).
The organic fractions were combined and dried over anhydrous
magnesium sulfate. The solvent was decanted then removed in va-
cuo, and the remaining crude residue containing the 13-O-butyryl
analog was dissolved in 1 ml dry THF and was cooled to 0ºC. The re-
maining deprotection step with HF/pyridine is identical to the proce-
dure described above for the synthesis of the 10-butyryl isomer. The
product (Rf = 0.33) was purified by preparative TLC (40:60 hexane/
ethyl acetate) to yield pure 13-butyryl-10-deacetylbaccatin III (5 mg,
21% [without optimization of the synthesis; based on the 7,10-bis(tri-
ethylsilyl)-10-deacetylbaccatin III], 95% purity by 1H-NMR). 1H-NMR
(300 MHz, CDCl3) d: 0.99 (t, J = 7.5 Hz, CH3CH2CH2C=O), 1.10 (s,
H16), 1.20 (s, H17), 1.25 (tq, J = 7.5 Hz, J = 7.5 Hz, CH3CH2CH2
C=O), 1.73 (s, H19), 1.84 (m, H6b), 2.02 (s, H18), 2.20 (d, J = 9.0 Hz,
H14), 2.30 (s, CH3C=O at C4), 2.40 (m, CH3CH2CH2C=O),
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3152.58 (m, H6a), 3.93 (d, J = 7.2 Hz, H3), 4.16 (d, J = 8.2 Hz, H20b), 4.20
(dd, J = 10.8 Hz, J = 6.9 Hz, H7), 4.30 (d, J = 8.4 Hz, H20a), 4.95 (dd,
J = 9.6, J = 1.8 Hz, H5), 5.20 (s, H10), 5.65 (d, J = 6.9 Hz, H2), 6.17
(t, J = 8.7, H13), 7.46–8.08 (aromatic-H).
Expression, Activity Assay, and Partial Purification of DBAT
The large-scale (6L) procedure for the expression of the recombi-
nant DBAT from pCWori+ in E. coli JM109 cells, activity assay, and
partial purification of the enzyme by anion exchange chromatogra-
phy has been described previously [18], with the following modifica-
tions of the assay and purification schemes. After eluting the target
protein from a column of O-diethylaminoethylcellulose (2.53 14 cm,
Whatman DE-52) at z100 mM NaCl in 25 mM MOPSO (3-(N-
morpholino)-2-hydroxypropanesulfonic acid) buffer containing
3 mM dithiothreitol, fractions containing DBAT activity were com-
bined (50 ml) and concentrated (Amicon Diaflo YM 30 membrane,
Millipore, Billerica, MA). The DBAT concentration was estimated to
be at w140 mg/ml, as determined by SDS-PAGE and Coomassie
blue staining.
Screening for Productive CoA Substrates and Analysis
of Products
The general DBAT assay contained a 1 ml aliquot of the dialyzed
protein (w140 mg), which was incubated with [13-3H]-10-deacetyl-
baccatin III (75 mM, 90 nCi, specific activity at 1.2 Ci/mol) and an
acyl-CoA (500 mM) for 1 hr at 31ºC. The reaction was then quenched
by extraction with ethyl acetate, and the solvent was concentrated
in vacuo. The residue was dissolved in 50 ml acetonitrile and ana-
lyzed by radio-HPLC. The sample was loaded onto an Econosphere
C18 column (5 mm; 250 3 4.6 mm) (Alltech, Mentor, OH), eluted iso-
cratically with 40:60 (vol/vol) acetonitrile/water at 1 ml/min. Isolated
crude product derived from DBAT assays incubated with productive
CoA esters (acetyl-, propionyl-, and butyryl-CoA thioesters) each
showed a single, major radioactivity peak with a unique chromato-
graphic retention time upon elution from the HPLC column at 5.53,
6.73, and 8.63 min, respectively (cf. Figure 3).
To confirm the identity of each novel 10-acylbaccatin III product
made by DBAT, each productive acyl-coenzyme cosubstrate
(500 mM) was incubated separately in 20 ml assays for 3 hr with
DBAT (1.1 mg) and unlabeled 10-deacetylbaccatin III (500 mM) buff-
ered with 25 mM MOPSO buffer containing 3 mM dithiothreitol and
100 mM sodium chloride. The putative target product was purified
by preparative TLC (silica gel developed with a mobile phase of
40:60 hexane/ethyl acetate); the TLC retention factor (Rf) of both
products isolated from DBAT assays containing the productive sub-
strates propionyl-CoA and butyryl-CoA were virtually identical at
w0.40. The TLC-purified material was further purified by reverse-
phase HPLC eluted isocratically with 50:50 (vol/vol) acetonitrile/wa-
ter at 1 ml/min with UV monitoring (A228) of the effluent. The products
eluting from the column with identical retention times as those for
the radioactive products derived from the corresponding analytical
radiochemical assays (described earlier) were isolated. The solvent
from each fraction containing purified product was evaporated, and
the residue was dissolved in deuterated chloroform as internal stan-
dard for analysis by proton nuclear magnetic resonance spectros-
copy (1H-NMR). Purified product (w1 mg, 1.6 mmol) isolated from
the preparative-scale DBAT assay incubated with propionyl-CoA
was sufficient for 1H-NMR analysis, while the low concentration of
the sample (at% 0.1 mg, 0.16 mmol) isolated from a similar assay in-
cubated instead with butyryl-CoA was below the detection limits of
1H-NMR.
Comparison of the retention time on C18 reverse-phase HPLC of
the biosynthetically derived butyryl baccatin isomer to those of au-
thentic 7-, 10-, and 13-butanoyl-10-deacetylbaccatin III isomers
was conducted to assess the regiochemistry of the biosynthetic
product. Briefly, a preparative-scale (20 ml) assay containing bu-
tyryl-coenzyme (500 mM) was incubated for 3 hr with DBAT (1.1 mg)
and unlabeled 10-deacetylbaccatin III (500 mM) buffered with
25 mM MOPSO buffer containing 3 mM dithiothreitol and 100 mM
sodium chloride. The assay was extracted with ethyl acetate (3 3
20 ml), and the organic solvent was dried over magnesium sulfate,
decanted, and evaporated in vacuo. The remaining residue of crude
product was dissolved in acetonitrile (50 ml), a fraction (10 ml) was in-
jected onto a reverse-phase HPLC column that was eluted isocrati-cally with 60:40 acetonitrile/water, and the effluent was monitored at
228 nm. Each synthetic authentic butyryl-10-deacetylbaccatin III
standard (see above in Experimental Procedures) was indepen-
dently assessed by separately dissolvingw1 mg of each in acetoni-
trile (300 ml), a fraction of each (2 ml) was injected onto the HPLC
reverse-phase column eluted with 60:40 acetonitrile/water, and the
effluent was monitored at 228 nm. After the retention times of
authentic 7-, 10-, and 13-butyryl-10-deacetylbaccatin III were estab-
lished at 8.56 min, 6.51 min, and 6.35 min, respectively, an equimolar
mixture of the butyryl isomers was prepared in acetonitrile (100 ml),
and a fraction (2 ml) was injected onto the HPLC reverse-phase col-
umn eluted with 60:40 acetonitrile/water and UV monitoring
at 228 nm (cf. Figure 4). The HPLC-UV profile of the mixture of authen-
tic standards was compared to that of the de novo biosynthetic
product.
Additionally, a fraction of each isolated acylbaccatin was further
analyzed by combined liquid chromatography-mass spectrometry
(LC-ESI/MS) or fast atom bombardment mass spectrometry (FAB-
MS). Diagnostic ions with ion abundance are as follows. FAB ioniza-
tion (positive ion mode) of the putative baccatin III: m/z 587 (MH+,
43%), 527 (M+ 2 C(O)CH3, 43%), and 509 (m/z 527 2 H2O, 14%),
and the putative 10-propionyl-10-deactylbaccatin III: m/z 601
(MH+, 55%), 527 (M+ 2 C(O)CH2CH3, 40%), and 509 (m/z 527 2
H2O, 10%); LC-electrospray ionization (positive ion mode) of puta-
tive 10-butyryl-10-deacetylbaccatin III: m/z 615 (MH+, 10%), 527
(M+ 2 C(O)CH2CH2CH3, 65%), and 509 (m/z 527 2 H2O, 24%);
LC-electrospray ionization (positive ion mode) of authentic 10-deace-
tylbaccatin III: m/z 545 (MH+, 12%), 527 (M+ 2 H2O, 32%) and 509
(m/z 527 2 H2O, 10%).
Kinetic Evaluation of Competing Substrates
The procedure used to calculate the relative kinetic constants of
DBAT for multiple CoA substrates was adapted from a method
used to calculated the specificity constants for a NodH sulfotrans-
ferase [38]; this relative kinetics evaluation method was advanta-
geous toward conserving the radiolabeled 10-deacetylbaccatin III
cosubstrate by reducing the duplicate assays required to construct
parallel kinetic plots for each acyl-CoA substrate. In brief, evalua-
tions of the linearity of product formation with respect to time and
protein concentration were first established with the natural sub-
strates, and then the concentration of acetyl-CoA (5–100 mM) was
independently varied while the [13-3H]-10-deacetylbaccatin III
(400 mM, 0.49 mCi at 1.2 Ci/mol) was maintained at saturation. Assay
conditions and analysis were performed as described previously
[18]. A double reciprocal plot was constructed for the data set,
and the equation of the best-fit line (R2 = 0.98) was determined
(Microsoft Excel 2003, Microsoft Corporation, Redmond, WA) to cal-
culate the Vmax and Km.
The substrate specificity of the catalytically productive CoA thio-
esters was assessed by mixing each thioester (each at 50 mM) in
a single assay tube, along withw30 mg DBAT enzyme and unlabeled
10-deacetylbaccatin III (500 mM), and incubating for 1 hr. The prod-
uct ratio of each individual novel acylbaccatin III and baccatin III
(NABn/Bacc, where n = derived acylbaccatin III product) formed in
the mixed reaction was used along with the specificity constant
(Vmax/Km) of DBAT for acetyl-CoA to calculate the relative specificity
constant of each surrogate acyl-CoA substrate: relative (Vmax/Km)n =
([NABn/Bacc] 3 [Vmax/Km]).
In Vivo Conversion of 10-Deacetylbaccatin III to Baccatin III
by Recombinant DBAT in E. coli
10-Deacetylbaccatin III (100 mM) was fed to a 100 ml culture of trans-
formed JM109 E. coli expressing the DBAT protein from pCWori+.
The bacteria were grown to A600 = 1.0 at 37ºC with ampicillin selec-
tion, then expression was induced with 1 mM isopropyl-D-thiogalac-
toside, and the transformed bacteria were grown at 31ºC for 18 hr.
The approximate acetyl-CoA concentration in these transformed
JM109 E. coli cells was assessed to be at saturation (i.e., >100 mM)
for DBAT (atw30 mg/ml), as determined by assaying an aliquot of su-
pernatant, without purification, from a cell-free extract of bacterial
lysate as follows. A 1 ml aliquot of cell-free extract of the bacteria
was incubated for 1.5 hr with radiolabeled substrate [13-3H]-10-
deacetylbaccatin III at saturation (250 mM and 500 mM), with no exog-
enous acetyl-CoA added. Extraction of the assay supernatant with
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316ethyl acetate (2 3 1 ml), evaporation of solvent, and radio-HPLC
analysis of the residue dissolved in 50 ml acetonitrile revealed that
baccatin III was produced at maximum velocity. Analogously,
when the cofactor was removed from E. coli extracts by partial pu-
rification of DBAT by anion exchange chromatography prior to the
addition of substrate, standard assays containing [13-3H]-10-deacet-
ylbaccatin III (at saturation) and exogenous acetyl-CoA added at
250 mM revealed zero order production of baccatin III (i.e., DBAT
was at Vmax), as determined by radio-HPLC analysis of the effluent
and comparison to a kinetic curve for these substrates. This obser-
vation suggested that the acetyl-CoA present in the cell-free extract
(100 ml) of JM109 cells atA600z 1.0 isR 250 mM, which is consistent
with typical endogenous acetyl-CoA concentrations ranging be-
tween 20 and 600 mM in E. coli [39].
The bacteria cells from the in vivo feeding experiment described
above were harvested by centrifugation at 5000 3 g (10 min), and
the supernatant was isolated and saved for later. The cells were re-
suspended in 10 ml brine and lysed by brief sonication (five 20 s
bursts at 50% power [Misonix sonicator, Farmingdale, NY]). Lastly,
ethyl acetate (3 3 5 ml) was added, and the colloidal suspension
was extracted carefully to avoid emulsion.
To the supernatant, saved previously, was added NaCl (w30 g) to
minimize emulsion, and the resulting brine solution was extracted
with ethyl acetate (33 50 ml). The organic fractions from the extrac-
tion of the cellular debris and supernatant were processed sepa-
rately, dried with sodium sulfate, and filtered. The solvent of the
filtrates was evaporated, and the samples were dissolved in 200 ml
acetonitrile and analyzed by reverse-phase HPLC with UV monitor-
ing (A228) of the effluent (isocratic elution with 30:70 acetonitrile/
water) (cf. Figure 5). For a negative control experiment, JM109 cells
possessing a plasmid expressing TAX02 (a related Taxus-derived
2a-O-benzoyltransferase) were processed identically to bacteria ex-
pressing DBAT. The level of baccatin III produced by these cells was
below the detection limits of the analysis.
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